第二次自体干细胞移植对复发多发性骨髓瘤的影响:法国多中心真实生活研究。

IF 7.6 2区 医学 Q1 HEMATOLOGY HemaSphere Pub Date : 2024-07-29 DOI:10.1002/hem3.106
Axel André, Lydia Montes, Damien Roos-Weil, Laurent Frenzel, Marguerite Vignon, Thomas Chalopin, Pierre-Edouard Debureaux, Alexis Talbot, Agathe Farge, Fabrice Jardin, Karim Belhadj, Bruno Royer, Jean-Pierre Marolleau, Bertrand Arnulf, Pierre Morel, Stéphanie Harel
{"title":"第二次自体干细胞移植对复发多发性骨髓瘤的影响:法国多中心真实生活研究。","authors":"Axel André,&nbsp;Lydia Montes,&nbsp;Damien Roos-Weil,&nbsp;Laurent Frenzel,&nbsp;Marguerite Vignon,&nbsp;Thomas Chalopin,&nbsp;Pierre-Edouard Debureaux,&nbsp;Alexis Talbot,&nbsp;Agathe Farge,&nbsp;Fabrice Jardin,&nbsp;Karim Belhadj,&nbsp;Bruno Royer,&nbsp;Jean-Pierre Marolleau,&nbsp;Bertrand Arnulf,&nbsp;Pierre Morel,&nbsp;Stéphanie Harel","doi":"10.1002/hem3.106","DOIUrl":null,"url":null,"abstract":"<p>A second autologous stem-cell transplantation (ASCT2) is considered for relapsed multiple myeloma (RMM) patients showing prolonged response after a first ASCT. However, given breakthrough treatments like anti-CD38 and immunotherapy, its role remains debated. We conducted a real-life study in 10 French centers (1996–2017) involving 267 RMM patients receiving ASCT2. The median age was 61 years, with 49% females. Most patients received melphalan 200 mg/m² before ASCT2, with low early mortality (1%). Very good partial response or better (VGPR+) rate post ASCT2 was 78%. Post ASCT2, 48% received consolidation therapy and 40% maintenance therapy. Median event-free survival (EFS) after ASCT2 was 2.6 years (95% confidence interval [CI]: 2.3–2.8), and 2-year EFS estimate was 63% (95% CI: 57–70). Median overall survival (OS) was 8.1 years (95% CI: 5.9–NA), and 2-year OS estimate was 92% (95% CI: 88–95). Multivariate analysis revealed that VGPR+ status and maintenance therapy post ASCT2 were associated with better EFS (hazard ratio [HR]: 0.6; 95% CI: 0.3–0.9, <i>p</i> = 0.012 and HR: 0.4; 95% CI: 0.3–0.6, <i>p</i> &lt; 0.001, respectively) and OS (HR: 0.4; 95% CI: 0.2–0.9, <i>p</i> = 0.017 and HR: 0.2; 95% CI: 0.1–0.4, <i>p</i> &lt; 0.001, respectively), while male sex correlated with poorer outcomes for EFS (HR: 2.5; 95% CI: 1.7–3.7, <i>p</i> &lt; 0.001) and OS (HR: 2.7; 95% CI: 1.4–4.9, <i>p</i> = 0.002). Overall, ASCT2 appeared efficient with low toxicity in RMM. Maintenance therapy was associated with extended EFS and OS, particularly in patients with VGPR+ status post ASCT2. These findings underscore ASCT2's potential in RMM when coupled with maintenance therapy in selected patients.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":null,"pages":null},"PeriodicalIF":7.6000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11285034/pdf/","citationCount":"0","resultStr":"{\"title\":\"Impact of second autologous stem-cell transplantation at relapsed multiple myeloma: A French multicentric real-life study\",\"authors\":\"Axel André,&nbsp;Lydia Montes,&nbsp;Damien Roos-Weil,&nbsp;Laurent Frenzel,&nbsp;Marguerite Vignon,&nbsp;Thomas Chalopin,&nbsp;Pierre-Edouard Debureaux,&nbsp;Alexis Talbot,&nbsp;Agathe Farge,&nbsp;Fabrice Jardin,&nbsp;Karim Belhadj,&nbsp;Bruno Royer,&nbsp;Jean-Pierre Marolleau,&nbsp;Bertrand Arnulf,&nbsp;Pierre Morel,&nbsp;Stéphanie Harel\",\"doi\":\"10.1002/hem3.106\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>A second autologous stem-cell transplantation (ASCT2) is considered for relapsed multiple myeloma (RMM) patients showing prolonged response after a first ASCT. However, given breakthrough treatments like anti-CD38 and immunotherapy, its role remains debated. We conducted a real-life study in 10 French centers (1996–2017) involving 267 RMM patients receiving ASCT2. The median age was 61 years, with 49% females. Most patients received melphalan 200 mg/m² before ASCT2, with low early mortality (1%). Very good partial response or better (VGPR+) rate post ASCT2 was 78%. Post ASCT2, 48% received consolidation therapy and 40% maintenance therapy. Median event-free survival (EFS) after ASCT2 was 2.6 years (95% confidence interval [CI]: 2.3–2.8), and 2-year EFS estimate was 63% (95% CI: 57–70). Median overall survival (OS) was 8.1 years (95% CI: 5.9–NA), and 2-year OS estimate was 92% (95% CI: 88–95). Multivariate analysis revealed that VGPR+ status and maintenance therapy post ASCT2 were associated with better EFS (hazard ratio [HR]: 0.6; 95% CI: 0.3–0.9, <i>p</i> = 0.012 and HR: 0.4; 95% CI: 0.3–0.6, <i>p</i> &lt; 0.001, respectively) and OS (HR: 0.4; 95% CI: 0.2–0.9, <i>p</i> = 0.017 and HR: 0.2; 95% CI: 0.1–0.4, <i>p</i> &lt; 0.001, respectively), while male sex correlated with poorer outcomes for EFS (HR: 2.5; 95% CI: 1.7–3.7, <i>p</i> &lt; 0.001) and OS (HR: 2.7; 95% CI: 1.4–4.9, <i>p</i> = 0.002). Overall, ASCT2 appeared efficient with low toxicity in RMM. Maintenance therapy was associated with extended EFS and OS, particularly in patients with VGPR+ status post ASCT2. These findings underscore ASCT2's potential in RMM when coupled with maintenance therapy in selected patients.</p>\",\"PeriodicalId\":12982,\"journal\":{\"name\":\"HemaSphere\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2024-07-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11285034/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"HemaSphere\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hem3.106\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"HemaSphere","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hem3.106","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

复发多发性骨髓瘤(RMM)患者在第一次自体干细胞移植(ASCT)后出现长期反应,可考虑进行第二次自体干细胞移植(ASCT2)。然而,鉴于抗CD38和免疫疗法等突破性治疗方法,其作用仍存在争议。我们在法国的10个中心开展了一项实际研究(1996-2017年),共有267名RMM患者接受了ASCT2。中位年龄为61岁,女性占49%。大多数患者在ASCT2前接受了美法仑200 mg/m²治疗,早期死亡率较低(1%)。ASCT2后的部分反应非常好或更好(VGPR+)率为78%。ASCT2后,48%的患者接受了巩固治疗,40%接受了维持治疗。ASCT2后的中位无事件生存期(EFS)为2.6年(95%置信区间[CI]:2.3-2.8),2年EFS估计值为63%(95% CI:57-70)。中位总生存期(OS)为8.1年(95% CI:5.9-NA),2年OS估计值为92%(95% CI:88-95)。多变量分析显示,VGPR+ 状态和 ASCT2 后的维持治疗与较好的 EFS 相关(危险比 [HR]:HR:0.6;95% CI:0.3-0.9,P = 0.012;HR:0.4;95% CI:0.3-0.6,P = 0.017;HR:0.2;95% CI:0.1-0.4,P = 0.002)。总体而言,ASCT2在RMM患者中疗效显著,毒性较低。维持治疗与延长 EFS 和 OS 相关,尤其是在 ASCT2 后 VGPR+ 状态的患者中。这些发现强调了ASCT2在RMM中的潜力,如果在选定的患者中配合维持治疗的话。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Impact of second autologous stem-cell transplantation at relapsed multiple myeloma: A French multicentric real-life study

A second autologous stem-cell transplantation (ASCT2) is considered for relapsed multiple myeloma (RMM) patients showing prolonged response after a first ASCT. However, given breakthrough treatments like anti-CD38 and immunotherapy, its role remains debated. We conducted a real-life study in 10 French centers (1996–2017) involving 267 RMM patients receiving ASCT2. The median age was 61 years, with 49% females. Most patients received melphalan 200 mg/m² before ASCT2, with low early mortality (1%). Very good partial response or better (VGPR+) rate post ASCT2 was 78%. Post ASCT2, 48% received consolidation therapy and 40% maintenance therapy. Median event-free survival (EFS) after ASCT2 was 2.6 years (95% confidence interval [CI]: 2.3–2.8), and 2-year EFS estimate was 63% (95% CI: 57–70). Median overall survival (OS) was 8.1 years (95% CI: 5.9–NA), and 2-year OS estimate was 92% (95% CI: 88–95). Multivariate analysis revealed that VGPR+ status and maintenance therapy post ASCT2 were associated with better EFS (hazard ratio [HR]: 0.6; 95% CI: 0.3–0.9, p = 0.012 and HR: 0.4; 95% CI: 0.3–0.6, p < 0.001, respectively) and OS (HR: 0.4; 95% CI: 0.2–0.9, p = 0.017 and HR: 0.2; 95% CI: 0.1–0.4, p < 0.001, respectively), while male sex correlated with poorer outcomes for EFS (HR: 2.5; 95% CI: 1.7–3.7, p < 0.001) and OS (HR: 2.7; 95% CI: 1.4–4.9, p = 0.002). Overall, ASCT2 appeared efficient with low toxicity in RMM. Maintenance therapy was associated with extended EFS and OS, particularly in patients with VGPR+ status post ASCT2. These findings underscore ASCT2's potential in RMM when coupled with maintenance therapy in selected patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
HemaSphere
HemaSphere Medicine-Hematology
CiteScore
6.10
自引率
4.50%
发文量
2776
审稿时长
7 weeks
期刊介绍: HemaSphere, as a publication, is dedicated to disseminating the outcomes of profoundly pertinent basic, translational, and clinical research endeavors within the field of hematology. The journal actively seeks robust studies that unveil novel discoveries with significant ramifications for hematology. In addition to original research, HemaSphere features review articles and guideline articles that furnish lucid synopses and discussions of emerging developments, along with recommendations for patient care. Positioned as the foremost resource in hematology, HemaSphere augments its offerings with specialized sections like HemaTopics and HemaPolicy. These segments engender insightful dialogues covering a spectrum of hematology-related topics, including digestible summaries of pivotal articles, updates on new therapies, deliberations on European policy matters, and other noteworthy news items within the field. Steering the course of HemaSphere are Editor in Chief Jan Cools and Deputy Editor in Chief Claire Harrison, alongside the guidance of an esteemed Editorial Board comprising international luminaries in both research and clinical realms, each representing diverse areas of hematologic expertise.
期刊最新文献
30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis How to diagnose acid sphingomyelinase deficiency (ASMD) and Niemann–Pick disease type C from bone marrow and peripheral blood smears GPRASP protein deficiency triggers lymphoproliferative disease by affecting B-cell differentiation Issue Information Mitochondrial retention in mature red blood cells from patients with sickle cell disease is associated with stress erythropoiesis but not with proinflammatory state
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1